SSC 2026 Guidelines now available — 129 adult & 61 pediatric recommendations View guidelines →
Evidence-based guideline for prevention, assessment, and management of oral and GI mucositis in cancer patients receiving chemotherapy, radiation, and stem cell transplantation.
Evidence-based guideline for recognition, grading, and management of immune-related adverse events (irAEs) across all organ systems in patients receiving checkpoint inhibitor immunotherapy.
Evidence-based guideline for emetogenic risk classification, antiemetic regimen selection, and management of chemotherapy-induced nausea and vomiting.
Management of immune-mediated hematologic toxicities, ophthalmologic irAEs, combination immunotherapy toxicity profiles, rechallenge criteria, preexisting autoimmune disease, special populations, multidisciplinary triggers, and patient education.
Grade-based management of immune-mediated myocarditis, pericarditis, neurologic toxicities (myasthenia gravis, encephalitis, Guillain-Barre, neuropathy), nephritis, inflammatory arthritis, and myositis.
Patient assessment and grading tools for CINV including CTCAE and MASCC Antiemesis Tool, evidence-based non-pharmacological interventions, guideline implementation strategies, quality improvement metrics, and patient education.
Chemotherapy-induced diarrhea management, irinotecan-specific protocols, immune checkpoint inhibitor colitis, head and neck radiation mucositis, pelvic radiation enteritis, chemoradiation, TBI-related mucositis, palifermin in HSCT, and engraftment syndrome.
Grade-based management of immune-mediated endocrine toxicities (thyroid disorders, adrenal insufficiency, hypophysitis, type 1 diabetes) and pneumonitis including workup, corticosteroid protocols, hormone replacement, and immunosuppressive escalation.
Guideline-recommended antiemetic regimens by emetogenic risk level, multi-day chemotherapy protocols, oral chemotherapy CINV, radiation-induced nausea and vomiting, breakthrough and refractory CINV management, and considerations for pediatric, geriatric, and organ-impaired populations.
Evidence-based oral mucositis prevention including cryotherapy, photobiomodulation, palifermin, and basic oral care; pain management; nutritional support; infection management; agents with evidence against use.
Grade-based management of immune-mediated dermatologic toxicities (rash, pruritus, bullous pemphigoid, SJS/TEN), colitis/diarrhea, and hepatitis including workup, corticosteroid protocols, and immunosuppressive escalation.
Comprehensive review of antiemetic drug classes used in CINV prophylaxis and treatment: NK1 receptor antagonists, 5-HT3 receptor antagonists, corticosteroids, olanzapine, dopamine antagonists, benzodiazepines, and cannabinoids with complete dosing, pharmacokinetics, and adverse effect profiles.
Five-phase pathobiology model of mucositis, comprehensive grading scales (WHO, NCI CTCAE, OMAS), treatment-related and patient-related risk factors, and pre-treatment dental assessment.
Classes of immune checkpoint inhibitors, mechanism and epidemiology of irAEs, CTCAE grading, general management framework, corticosteroid protocols, immunosuppressive escalation, and infusion reactions.
Complete emetogenic risk classification of intravenous and oral chemotherapy agents (high, moderate, low, minimal), types of CINV, pathophysiology of chemotherapy-induced emesis, and patient- and treatment-related risk factors.